FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smallmolecule product candidates to address serious diseases, including oncology and obesity, today announced the pricing of its upsized underwritten public offering of 11,919,048 shares of its common stock at a public offering price of $10.50 per share, and, in lieu of common stock to certain investors, pre-funded ...

Shares of Terns Pharmaceuticals (TERN) , a clinical-stage company, soared 16.8% after the company announced positive top-line data from the early-stage single and multiple-ascending dose (SAD and MAD) obesity study. The phase I study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of its investigational, oral, small-molecule GLP-1R agonist, TERN-601, dosed once daily in healthy adults with obesity or overweight. Terns Reports Superior Weight Reduction With TERN-601 Per the data rea ...

Jose Luis Pelaez Inc/DigitalVision via Getty Images When I last wrote about Terns Pharmaceuticals, Inc. (NASDAQ:TERN) in July 2023, the company was in clinical trials with a leukemia drug and a drug for liver disease, and I rated it a buy on its prospects in those disease areas. Now TERN has reported results from a four-week study of its oral GLP-1 receptor agonist (TERN601), showing impressive weight loss, meaning the company might have itself a drug for obesity. This article takes a look at the weight los ...

FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smallmolecule product candidates to address serious diseases, including oncology and obesity, today announced that it has commenced a proposed underwritten public offering of $125 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its c ...

Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted) Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration Distinct drug properties support potential to be a leading GLP-1R agonist Plans to initiate Phase 2 clinical trial in 2025 Company to host conference call today at 8:00 am ET FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TE ...

Shares of Terns Pharmaceuticals, Inc. (TERN) , a clinical-stage biopharmaceutical company, rose 29.6% in the past three months compared with the industry's growth of 7.4%. The stock outperformed the sector and the S&P 500 Index during the said time frame. The outperformance can be attributed to encouraging pipeline progress of its obesity and oncology candidates. TERN Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research Terns Targets Lucrative Obesity Market Terns is developing a p ...

Shares of Terns Pharmaceuticals, Inc. (TERN) have gained 3.7% over the past four weeks to close the last trading session at $7.95, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.21 indicates a potential upside of 78.7%. The average comprises seven short-term price targets ranging from a low of $5.50 to a high of $22, with a standard deviation of $5.92. While the lowest esti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39926 Terns Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 98-1448275 (State or other juris ...

Exhibit 99.1 Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in September 2024 Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL) in chronic myeloid leukemia (CML) expected in December 2024 Cash, cash equivalents and marketable securities of $225 million, expected to provide runway into 2026 FOSTER CITY, Calif., August 5, 2 ...

FOSTER CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smallmolecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Elona Kogan, Esq., as chief legal officer, effective immediately. Ms. Kogan brings a wealth of industry experience and has successfully guided several biotechnology companies through trans ...